Clinical translational research of chimeric antigen receptor-T (CAR-T) cells for the treatment of relapsed and refractory B-cell lymphoma/leukemia.
10.7534/j.issn.1009-2137.2014.04.048
- Author:
Shun-Zong YUAN
1
;
Hang SU
2
Author Information
1. Department of Lymphoma, Head and Neck Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China.
2. Department of Lymphoma, Head and Neck Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China. E-mail: suhang307@126.com.
- Publication Type:Journal Article
- MeSH:
Cell- and Tissue-Based Therapy;
Humans;
Lymphoma, B-Cell;
therapy;
Receptors, Antigen, T-Cell;
immunology;
therapeutic use;
Remission Induction;
Translational Medical Research
- From:
Journal of Experimental Hematology
2014;22(4):1137-1141
- CountryChina
- Language:Chinese
-
Abstract:
B-cell lymphoma and leukemia are the most common subtypes of malignant lymphomas. Relapse and refractory to multiple therapy are the main reasons of treatment failure. As the classical anti-tumor methods, surgery, radiation, chemotherapy and palliative therapy have cured lots of cancer patients. However, each year many patients still died of different kinds of hard-to-treat cancers. Although the ratio of complete remission of B-cell lymphoma/leukemia patients particularly with CD20 positive mature B cell malignancies has been largely increased after the application of Rituximab in clinic, nearly 20%-40% patients still died due to relapse and refractory to the treatment. During last five years, the development of chimeric antigen receptor-T (CAR-T) cells, especially CD19 CAR-T cells, which can recognize CD19 specifically expressed on B cells and have been demonstrated to be significantly effective to relapsed and refractory B cell lymphoma/leukemia in clinical trials, has gradually attracted extensively concerning from researchers and clinicians. Many medical institutions all over the world (besides in China) have registered the clinical trials for B-cell lymphoma/leukemia patients by use of CAR-T cells. In this review, we summarize the developmental history, the main ongoing clinical trials and proved potential adverse affects of CD19 CAR-T cells for the treatment of patients with B-cell lymphoma/leukemia.
